Davis Thomas Andrew

AVANT Immunotherapeutics, Inc.

Executive VP & CMO

Avg. Two Year Performance

56% Avg. Purchase Return 25% Compound

No Sale Track Record

Holdings: 1.01K shares

Last Three Months: 23-Aug-24 -- 22-Nov-24

0 Net Amount

Buy:	0	--
Sell:	0	--

Sentiment

Company Sentiment

Diagnostic Substances

Drugs

Two Year Chart

23-Nov-22 -- 22-Nov-24

Price ($)

Two Year Stock Price Chart

Sentiment

Company Sentiment

Most Recent Insider Transactions